Raising a $27m deep tech growth round in a downturn
AccelerComm has announced a $27m Series B, testament to the resilient nature of deep tech.
Accelerating Drug Discovery From One Year to Less Than One Day
OMass Therapeutics are an Oxford biotechnology company spun out of Oxford University harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. The company’s suite of proprietary technologies delivers superior resolution to traditional pharmacology assays enabling a clearer, more detailed picture of how a putative ligand engages a protein target, assessing binding and function in parallel. The company is building a pipeline of small molecule therapeutics to bring life-changing benefits to patients suffering from immunology and genetic disorders. OMass is backed by Syncona Ltd, Oxford Sciences Innovation and Oxford University.
See full article here: https://yellowdog.co/case_studies/accelerating-drug-discovery-omass-therapeutics/
